[ Home ] [ Controlled Substances ] [ Stimulants ]
NEA
|
Etilamfetamine (Apetinil) is a stimulant drug of amphetamine chemical class. It is an N-substituted amphetamine with an ethyl group on the amphetamine backbone. It was used as an anorectic or appetite suppressant. Etilamfetamine is a psychoactive drug, which can be used as a recreational drug. Etilamfetamine has been abused as a "designer drug" alternative to amphetamine and possibly methamphetamine. It is a dopamine releasing agent.
Etilamfetamine (Apetinil):
https://drugs.ncats.io/drug/022YON1XMX
https://www.caymanchem.com/msdss/11557m.pdf
It was invented in the early 20th century and was subsequently used as an anorectic or appetite suppressant in the 1950s, but was not as commonly used as other amphetamines. was largely discontinued once newer drugs such as phenmetrazine were introduced. It most likely acts primarily as a dopamine releasing agent. Its activity as a norepinephrine or serotonin releasing agent is not known. Ethylamphetamine can be used as a recreational drug and, while its prevalence is less than amphetamine's, it is still encountered as a substance taken for recreational purposes. Ethylamphetamine produces effects similar to amphetamine and methamphetamine, though its potency is less. At equipotent dosage, ethylamphetamine is subjectively less euphorigenic.
Danish biotech Orbis secures $94m to develop oral versions of biologics - in a Series A funding round to advance the development of its next-generation orally dosable macrocycle drugs, which the company calls ⁿCycles. The financing was led by New Enterprise Associates (NEA) ... Monday January 06, 2025 - msn.com Orbis Medicines bags €90 million Series A to develop oral competitors of biologics - Orbis Medicines secures €90M Series A to develop innovative oral macrocycles, offering cost-effective alternatives to biologic drugs and targeting chronic disease markets. Ouro, backed by GSK, joins hunt to bring bispecifics to autoimmune disease - NEW YORK (PIX11) — A young man, homeless and disheveled, was surrounded by a joint response team made up of two NYPD officers, a social worker, and a nurse. After protesting for several minutes — with ... Fire1 raises $120M for breakthrough heart failure management tech - Fire1 announced today that it completed a $120 million financing round to accelerate the advancement of its heart failure management system. FIRE1 heats up with $120M for its heart failure monitor implant - Things are heating up for FIRE1, which posted a $120 million funding round to support its implant for tracking the hidden signs of heart failure. | The Dublin-based company also announced that the FDA ... Aviceda raises $207.5m for eye drug, and other financings - Aviceda Therapeutics has got biotech financing in 2025 off to a flying start by raising $207.5 million to take its lead drug for sight-robbing disease geographic atrophy (GA) into pivotal testing. Kure Beach Police warning residents of scammers posing as Sheriff’s Office - Kure Beach Police is warning residents of a scam where a person is posing as the New Hanover County Sheriff’s Office.
| ||
| Stimulants | Link to this page |